GENB Generate Biomedicines, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2100782 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets26.1%
Debt / equity0.00x
Current ratio5.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $4.22M | $6.31M | $7.22M | $9.63M | $10.13M | $8.82M |
| R&D expense | $82.25M | $64.33M | $57.81M | $62.15M | $59.73M | $46.83M |
| SG&A expense | $13.47M | $13.60M | $13.52M | $10.29M | $10.54M | $10.15M |
| Operating income | -$91.51M | -$71.61M | -$64.11M | -$62.81M | -$60.15M | -$48.15M |
| Interest expense | $192,000 | $155,000 | $182,000 | $253,000 | $307,000 | $368,000 |
| Pretax income | -$87.61M | -$67.20M | -$61.69M | -$60.00M | -$56.70M | -$44.26M |
| Income tax | $49,000 | $53,000 | $28,000 | $34,000 | $44,000 | $56,000 |
| Net income | -$87.66M | -$67.25M | -$61.45M | -$53.62M | -$52.43M | -$41.69M |
| EBITDA | -$87.81M | -$68.41M | -$60.84M | -$59.51M | -$56.85M | -$44.74M |
| EPS (basic) | -0.68 | -0.52 | -1.07 | -1.97 | -1.94 | -1.62 |
| EPS (diluted) | -0.68 | -0.52 | -1.07 | -1.97 | -1.94 | -1.62 |
| Weighted avg. shares (diluted) | 128.51M | 128.24M | 64.87M | 33.04M | 33.00M | 32.79M |
| Balance sheet | ||||||
| Cash & equivalents | $140.35M | $135.36M | $160.57M | $118.52M | $154.26M | $220.61M |
| Short-term investments | $263.86M | $322.06M | $356.07M | — | — | — |
| Current assets | $414.64M | $470.25M | $535.39M | — | — | — |
| PP&E, net | $38.65M | $27.30M | $27.84M | — | — | — |
| Total assets | $515.89M | $561.69M | $625.74M | — | — | — |
| Current liabilities | $82.72M | $56.64M | $58.39M | — | — | — |
| Total liabilities | $134.73M | $105.64M | $110.94M | — | — | — |
| Shareholders' equity | $381.16M | $456.05M | $514.80M | -$566.44M | -$517.85M | -$471.00M |
| Shares outstanding | 129.02M | 128.27M | 128.19M | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$54.86M | -$57.94M | -$80.39M | -$48.43M | -$48.75M | -$53.18M |
| Capital expenditure | $2.15M | $933,000 | $3.78M | $235,000 | $154,000 | $751,000 |
| Free cash flow | -$57.01M | -$58.88M | -$84.17M | -$48.66M | -$48.91M | -$53.93M |
| Investing cash flow | $56.36M | $33.31M | -$259.93M | $9.18M | -$17.07M | $75.53M |
| Financing cash flow | $3.49M | -$579,000 | $378.89M | $3.79M | -$263,000 | $20.56M |
| Depreciation & amortization | $3.70M | $3.20M | $3.27M | $3.30M | $3.30M | $3.41M |
| Stock-based compensation | $8.06M | $8.24M | $6.39M | $4.82M | $5.49M | $4.74M |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.